Published in Lancet on October 22, 1983
Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A (2000) 2.03
Decreased C3b receptors (CR1) on erythrocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1986) 1.09
Prevention of immune precipitation by purified classical pathway complement components. Clin Exp Immunol (1984) 1.09
Difference in the biological properties of the two forms of the fourth component of human complement (C4). Clin Exp Immunol (1986) 1.03
Prevention of immune precipitation by purified components of the alternative pathway. Clin Exp Immunol (1985) 1.00
Guinea pigs with inherited deficiencies of complement components C2 or C4 have characteristics of immune complex disease. J Clin Invest (1986) 0.92
The role of C1, C1-inactivator and C4 in modulating immune precipitation. Clin Exp Immunol (1985) 0.90
Superoxide anion production by neutrophils is associated with prevalent clinical manifestations in systemic lupus erythematosus. Clin Rheumatol (2007) 0.88
Purification of a plasma protein that inhibits complement-mediated prevention of immune precipitation. Immunology (1988) 0.88
BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells. Immunology (1988) 0.84
Familial properdin deficiency associated with chronic discoid lupus erythematosus. Clin Exp Immunol (1989) 0.84
Functional deficiency of complement factor D in a monozygous twin. Clin Exp Immunol (1984) 0.83
Disseminated gonococcal infection associated with deficiency of the second component of complement. Postgrad Med J (1991) 0.83
Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a). Clin Exp Immunol (1986) 0.83
Metabolites of procainamide and practolol inhibit complement components C3 and C4. Biochem J (1988) 0.81
Immunohistochemical localization of a plasma protein (glycoprotein 60) which inhibits complement-mediated prevention of immune precipitation. Immunology (1990) 0.77
The plasma protein which inhibits complement-mediated prevention of immune precipitation is an Fc binding protein. Immunology (1989) 0.77
Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation. Immunology (1990) 0.76
The aetiology and pathogenesis of major systemic vasculitides. Postgrad Med J (1986) 0.75
Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. N Engl J Med (1979) 3.02
Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet (1976) 3.00
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Inhibition of immune precipitation by complement. Clin Exp Immunol (1980) 2.72
The role of complement and its receptor in the elimination of immune complexes. N Engl J Med (1986) 2.63
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
The complement abnormalities of lipodystrophy. N Engl J Med (1976) 2.40
Value of immune-complex assays in diagnosis and management. Lancet (1978) 2.39
Relapses in Wegener's granulomatosis: the role of infection. Br Med J (1980) 2.29
Remission of myasthenia gravis following plasma-exchange. Lancet (1976) 2.25
Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clin Exp Immunol (1982) 2.20
The effect of defibrination on nephrotoxic serum nephritis in rabbits. Clin Sci (1972) 2.11
Glomerular deposition of properdin in Henoch-Schönlein syndrome and idiopathic focal nephritis. Br Med J (1973) 2.07
Wegener's granulomatosis: observations on 18 patients with severe renal disease. Q J Med (1983) 2.07
Mesangiocapillary nephritis, partial lipodystrophy, and hypocomplementaemia. Lancet (1973) 2.00
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
Enhanced allergic tissue injury in Goodpasture's syndrome by intercurrent bacterial infection. Br Med J (1977) 1.92
Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet (1983) 1.87
The role of polymorphonuclear leucocytes in the autologous phase of nephrotoxic nephritis. Clin Exp Immunol (1975) 1.75
Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet (1977) 1.71
Studies of serum complement in the hypocomplementaemic nephritides. Clin Exp Immunol (1974) 1.67
A quantitative evaluation of anticoagulants in experimental nephrotoxic nephritis. Clin Exp Immunol (1975) 1.61
Ectosomes released by human neutrophils are specialized functional units. J Immunol (1999) 1.54
Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol (1993) 1.53
The role of C3 in the autologous phase of nephrotoxic nephritis. Clin Exp Immunol (1976) 1.51
Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis (1990) 1.50
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
Albumin metabolism in chronic renal failure. Clin Sci (1970) 1.46
The immunogenetic basis of autoimmunity. Autoimmunity (1990) 1.42
Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int (1991) 1.40
Delayed removal of renal-bound antigen in decomplemented rabbits with acute serum sickness. Clin Exp Immunol (1978) 1.38
Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31
Hypocomplementaemic membranoproliferative glomerulonephritis and nephrotic syndrome associated with partial lipodystrophy of the face and trunk. Proc R Soc Med (1972) 1.31
Seasonal nephrotic syndrome. Description and immunological findings. Clin Allergy (1975) 1.29
Complement deficiency and nephritis. A report of a family. Lancet (1980) 1.27
Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome. Lancet (1978) 1.23
Defibrination with ancrod in nephrotoxic nephritis in rabbits. Kidney Int (1976) 1.23
Isolated glomerulonephritis with mesangial IgA deposits. Br Med J (1975) 1.20
Ectosomes as modulators of inflammation and immunity. Clin Exp Immunol (2010) 1.19
Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis. Clin Exp Immunol (1981) 1.19
Observations on calcium metabolism in the nephrotic syndrome. Q J Med (1967) 1.17
Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest (1994) 1.16
C3 breakdown by serum from patients with acute post-streptococcal nephritis. Lancet (1972) 1.16
Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis (2001) 1.15
The effects of defibrination with ancrod in experimental allergic glomerular injury. Clin Exp Immunol (1975) 1.15
Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J Invest Dermatol (1999) 1.14
Alllergic response to glomerular basement membrane in patients with glomerulonephritis. Lancet (1972) 1.14
Inherited deficiency of the fourth component of human complement. Immunodefic Rev (1988) 1.14
Total body calcium by whole body neutron activation: new technique for study of bone disease. Br Med J (1968) 1.12
Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med (1982) 1.12
Clusterin in renal tissue: preferential localization with the terminal complement complex and immunoglobulin deposits in glomeruli. Clin Exp Immunol (1992) 1.12
Guinea-pig nephrotoxic nephritis. I. The role of complement and polymorphonuclear leucocytes and the effect of antibody subclass and fragments in the heterologous phase. Clin Exp Immunol (1975) 1.11
Anti-glomerular basement membrane autoantibodies in the Brown Norway rat: detection by a solid-phase radioimmunoassay. J Immunol Methods (1983) 1.11
Plasma exchange in myasthenia gravis. Lancet (1977) 1.10
Identification of membrane-bound CR1 (CD35) in human urine: evidence for its release by glomerular podocytes. J Exp Med (1994) 1.08
Murine clusterin: molecular cloning and mRNA localization of a gene associated with epithelial differentiation processes during embryogenesis. J Cell Biol (1993) 1.07
Hepatitis C: a possible etiology for cryoglobulinaemia type II. Clin Exp Immunol (1992) 1.07
Metabolism of the third component of complement (C3) in normal human subjects. Clin Sci Mol Med (1974) 1.07
Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum (1999) 1.07
Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol (1988) 1.06
Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions. Clin Exp Immunol (1988) 1.06
Metabolism of human beta 1H: studies in man and experimental animals. Clin Exp Immunol (1979) 1.05
Plasma exchange in nephritis. Adv Nephrol Necker Hosp (1979) 1.04
Self-induced glomerulonephritis. Br Med J (1974) 1.04
Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest (1985) 1.04
Gastric acidity and iron absorption. Br J Haematol (1966) 1.03
Difference in the biological properties of the two forms of the fourth component of human complement (C4). Clin Exp Immunol (1986) 1.03
No complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int (2001) 1.02
Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis. Lancet (1973) 1.02
Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans. Clin Exp Immunol (1987) 1.02
Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation. J Clin Invest (1977) 1.02
Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol (1986) 1.01
Renal lesions of subacute infective endocarditis. Br Med J (1974) 1.01
The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro. Clin Exp Immunol (1976) 1.01
Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc (1982) 1.01
Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood (2000) 1.00
Landry-Guillain-Barré-Strohl polyneuritis and the nephrotic syndrome. Lancet (1973) 1.00
Skin lesions, angio-oedema, and hypocomplementaemia. Lancet (1974) 0.99
Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int (1994) 0.99
Complement-mediated inhibition of immune precipitation. II. Analysis by sucrose density gradient ultracentrifugation. Clin Exp Immunol (1982) 0.99
Cryoglobulins are not essential. Ann Rheum Dis (1998) 0.99
Membrane attack complex (MAC) deposits in skin are not always accompanied by S-protein and clusterin. J Invest Dermatol (1992) 0.99
Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J (1975) 0.98
Metabolism of radio-labelled C3: effects of in vivo activation in rabbits. Clin Exp Immunol (1974) 0.98
Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum (1988) 0.97
Academic medicine. BMJ (1992) 0.97
Partial lipodystrophy, meningococcal meningitis and nephritis. Dermatologica (1986) 0.96
Glomerulonephritis in a patient with complement factor I deficiency. Am J Kidney Dis (1999) 0.96
C3b receptors in glomerular disease. Clin Exp Immunol (1977) 0.95
Sarcoidosis and amyloidosis. Proc R Soc Med (1971) 0.95
Metabolism of complement factor D in renal failure. Kidney Int (1988) 0.94
Difference in the clustering of complement receptor type 1 (CR1) on polymorphonuclear leukocytes and erythrocytes: effect on immune adherence. Eur J Immunol (1990) 0.94
Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Methods (1994) 0.92
Release of vesicles enriched in complement receptor 1 from human erythrocytes. J Immunol (1993) 0.92
Studies on NEM-treated erythrocyte clearance in the rabbit, with special reference to the effects of circulating immune complexes. Clin Exp Immunol (1981) 0.92